We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets
News

Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets

Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets
News

Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The combination of Proteros’ structure guided discovery with Priaxon’s PPI-directed drug discovery platforms will be focused on the identification of novel small molecule modulators for PPI targets. As part of this collaboration, Proteros will apply its integrated Lead Discovery expertise and technologies in the field of structural biology, biophysics and screening. Priaxon will apply its proprietary drug discovery platform  Priaxplore®, which combines a proprietary PPI focused chemical space with special tailor made chemoinformatic methods for the identification of potential PPI modulators.

“The combination of Proteros’ strength in structural biology and biophysics with the Priaxon’s PPI focused drug discovery platform Priaxplore® forms an excellent basis to make PPI targets of high interest addressable by small molecule modulators" said Dr. Juergen Kolb, CEO of Priaxon.

Dr. Torsten Neuefeind, CEO of Proteros, stated: "We are very pleased to have formed this relationship with Priaxon. Both companies have complementary platforms as well as an established track-record. PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons’ validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner”.

Advertisement